Skip to main content
. 2018 Jul 25;12:1311–1316. doi: 10.2147/OPTH.S164184

Figure 2.

Figure 2

Kaplan–Meier analysis showing the probability of using systemic antiviral therapy in cytomegalovirus anterior uveitis.

Notes: In all 4 patients without corneal endothelial cell damage, systemic antiviral therapy could be terminated within 17 months, whereas 5 of the 8 patients (62.5%) with corneal endothelial damage had to continue systemic therapy to prevent recurrent inflammation or intraocular pressure elevation (P = 0.023, Wilcoxon signed-rank test).